-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

Russell P. "Rip" Wilson
Executive Vice President
and General Manager, Influenza
and General Manager, Influenza
Mr. Wilson is executive vice president and NanoFlu general manager with responsibility for leading the efforts to advance NanoFlu through global licensure. Mr. Wilson joined Novavax in 2011 as senior vice president, business development, and most recently was responsible for global business development, quality, and program management functions across the company’s entire pipeline. Prior to joining Novavax in November 2011, Mr. Wilson was most recently the chief financial officer at Supernus Pharmaceuticals. He was previously senior vice president, chief financial officer, and general counsel of Iomai Corporation, which was acquired in 2008 by Intercell AG, during which time he successfully negotiated a $128 million government contract with the Office of Biomedical Research and Development Authority (BARDA) at the US Department of Health and Human Services. Mr. Wilson was also the acting general counsel of North American Vaccine, Inc. until its acquisition by Baxter International in 2000. Mr. Wilson received a bachelor of arts degree in history from Princeton University and a master degree in business administration and a juris doctorate from the University of Virginia.